Unlock instant, AI-driven research and patent intelligence for your innovation.

Composite egg yolk antibody and pig spleen transfer factor product

A technology of pig spleen transfer factor and egg yolk antibody, which is applied in the field of antibody compound preparations, can solve the problems of economic loss, increased feed consumption, and increased cost of chicken farming, and achieve good preventive effects

Inactive Publication Date: 2017-01-04
QINGDAO RUNDA BIOTECH
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The highly contagious nature of the disease and the polyserotypic nature of the pathogen complicate and increase the cost of immunoprophylaxis
The growth of infected chickens is hindered, feed consumption increases, egg production and egg quality decrease, mortality rate increases, and often concurrent infection produces air sacculitis, resulting in broiler chickens being discarded during processing. Therefore, the disease often causes huge losses to the chicken industry. Economic losses

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Example 1: A method for preparing a composite product of egg yolk antibody and porcine spleen transfer factor, the steps are as follows:

[0020] (1) The preparation of egg yolk antibody can be any existing technology:

[0021] A. Select laying hens without specific pathogens and raise them in isolation in a clean farm. The laying hens are immunized three times, and each chicken is injected with Newcastle disease, infectious bronchitis, and avian influenza (H9) triple vaccine injection doses of 0.5 ml, 1.5ml, 2.0ml, each interval is 15 days;

[0022] B. 21 days after the third immunization, the eggs were collected, and the yolk antibody in the yolk was immunologically tested. The hemagglutination inhibitory titer of the yolk antibody in Newcastle disease and avian influenza (H9) reached 1:512 or more, and at the same time infectious bronchiectasis Eggs with a yolk antibody agar diffusion titer of 1:32 or more are high-immune eggs for Newcastle disease, infectious bronc...

Embodiment 2

[0028] Example 2: A method for preparing a composite product of egg yolk antibody and porcine spleen transfer factor, the steps are as follows:

[0029] (1) The preparation of egg yolk antibody can be any existing technology:

[0030] A. Select laying hens without specific pathogens and raise them in isolation in a clean farm. The laying hens are immunized three times, and each chicken is injected with Newcastle disease, infectious bronchitis, and avian influenza (H9) triple vaccine injection doses of 0.5 ml, 1.5ml, 2.0ml, each interval is 15 days;

[0031] B. 21 days after the third immunization, the eggs were collected, and the yolk antibody in the yolk was immunologically tested. The hemagglutination inhibitory titer of the yolk antibody in Newcastle disease and avian influenza (H9) reached 1:512 or more, and at the same time infectious bronchiectasis Eggs with a yolk antibody agar diffusion titer of 1:32 or more are high-immune eggs for Newcastle disease, infectious bronc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a composite egg yolk antibody and pig spleen transfer factor product. A prepared egg yolk antibody and a prepared pig spleen transfer factor which are resistant to newcastle diseases, infectious bronchitis and bird flu (H9) virus are prepared according to the mass ratio of 10.0-99.5 to 0.5-20.0 to obtain the composite product. According to the composite product, a modern egg yolk antibody extraction technology suitable for large-scale production and an optimized pig spleen transfer factor process are adopted, and the nonspecific immune effects of specific antibodies and the transfer factors of the newcastle diseases, the infectious bronchitis and the bird flu (H9) are combined, so that the composite egg yolk antibody and pig spleen transfer factor product can play the treating effect on the newcastle diseases, the infectious bronchitis and the bird flu (H9) and also has a good preventing effect.

Description

technical field [0001] The invention relates to an antibody compound preparation, in particular to a compound product of Newcastle disease, infectious bronchitis, bird flu (H9) egg yolk antibody and pig spleen transfer factor. Background technique [0002] Newcastle disease (ND), caused by Newcastle disease virus (NDV), is an acute, febrile, highly contagious infectious disease characterized by damage to the respiratory tract, digestive tract, and nervous system. Sexual epidemics can cause 100% morbidity and death of goslings within 15 days of age. It is listed as a Class A infectious disease by the International Organization for Animal Health (OIE), which seriously endangers the development of the breeding industry in countries all over the world. In recent years, with the wide application of Newcastle disease vaccine, the epidemic of Newcastle disease has been controlled to a certain extent, but it is accompanied by changes in the epidemic trend, mainly manifested as atypi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/42A61K38/19A61P31/16A61P31/14
CPCA61K39/42A61K38/19A61K2039/505A61K2039/552A61K2039/70A61K2300/00
Inventor 赵立媛王浩赵丹丹杜新永刘军伟刘长太
Owner QINGDAO RUNDA BIOTECH